SCHEMBL31551995

SCHEMBL31551995

COC(=O)c1cc(F)c(Br)c(C)c1NC(=O)NC(=O)C(Cl)(Cl)Cl

nearest known ligand 0.33

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.33
KDM4E B2RXH2 2/20 0.32
GAA P10253 2/20 0.31
PYGL P06737 1/20 0.31
MEN1 O00255 2/20 0.30
MAPT P10636 2/20 0.30
KMT2A Q03164 2/20 0.30
CASP3 P42574 1/20 0.30
SENP7 Q9BQF6 1/20 0.30
USP2 O75604 1/20 0.30
POLB P06746 1/20 0.30
HSD17B10 Q99714 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
HTT P42858 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24616284 0.89 SOS1 (0.36) SOS1KDM4EGAAPYGLMEN1
SCHEMBL24616425 0.88 DRD3 (0.34) KDM4EGAAMEN1MAPTKMT2A
SCHEMBL24616423 0.86 CFTR (0.34) SOS1KDM4EGAAMEN1MAPT
SCHEMBL29977115 0.81 TDP1 (0.36) KDM4EGAAMEN1MAPTKMT2A
SCHEMBL25814978 0.81 TDP1 (0.36) KDM4EGAAMEN1MAPTKMT2A
SCHEMBL26967305 0.80 KDM4E (0.40) SOS1KDM4EGAAPYGLMEN1
SCHEMBL29810959 0.80 SOS1 (0.40) SOS1
SCHEMBL24917968 0.79 SOS1 (0.39) SOS1KDM4EMAPTALDH1A1
SCHEMBL29810906 0.79 SOS1 (0.39) SOS1KDM4EMAPTALDH1A1
SCHEMBL31355666 0.78 SOS1 (0.36) SOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026101924-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2026-05-15 WO disclosed
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS INC (US) 2025-11-13 US disclosed
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-09-11 US disclosed
US-20250179093-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-06-05 US disclosed
WO-2025064542-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2025-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179093-A1 KRAS MODULATORS KRAS, NRAS, HRAS SOS1 121/4885KDM4E 3312/4885GAA 2015/4885
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS SOS1 213/4885KDM4E 1964/4885GAA 2385/4885
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS SOS1 213/4885KDM4E 1964/4885GAA 2385/4885
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS SOS1 213/4885KDM4E 1964/4885GAA 2385/4885
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS SOS1 24/4885KDM4E 4812/4885GAA 3456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.